ICECURE MEDICAL LTD (ICCM) Stock Fundamental Analysis
USA - NASDAQ:ICCM - IL0011224156 - Common Stock
0.6916 USD
-0.01 (-1.14%)
Taking everything into account, ICCM scores 2 out of 10 in our fundamental rating. ICCM was compared to 188 industry peers in the Health Care Equipment & Supplies industry. ICCM may be in some trouble as it scores bad on both profitability and health. ICCM is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ICCM had negative earnings in the past year.
ICCM had a negative operating cash flow in the past year.
In the past 5 years ICCM always reported negative net income.
ICCM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ICCM has a worse Return On Assets (-147.13%) than 87.23% of its industry peers.
ICCM has a worse Return On Equity (-538.91%) than 85.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -147.13% | ||
| ROE | -538.91% | ||
| ROIC | N/A |
ROA(3y)-89.11%
ROA(5y)-66.89%
ROE(3y)-136.41%
ROE(5y)-102.39%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 35.92%, ICCM is doing worse than 69.68% of the companies in the same industry.
In the last couple of years the Gross Margin of ICCM has grown nicely.
The Profit Margin and Operating Margin are not available for ICCM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.03%
GM growth 5Y4.86%
2. Health
2.1 Basic Checks
ICCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ICCM has been increased compared to 1 year ago.
ICCM has more shares outstanding than it did 5 years ago.
ICCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ICCM has an Altman-Z score of -15.63. This is a bad value and indicates that ICCM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -15.63, ICCM is not doing good in the industry: 83.51% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.70 indicates that ICCM is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.70, ICCM is not doing good in the industry: 70.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.63 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
A Current Ratio of 1.18 indicates that ICCM should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.18, ICCM is doing worse than 82.45% of the companies in the same industry.
A Quick Ratio of 0.88 indicates that ICCM may have some problems paying its short term obligations.
The Quick ratio of ICCM (0.88) is worse than 83.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.77% over the past year.
The Revenue has been growing slightly by 1.92% in the past year.
Measured over the past years, ICCM shows a quite strong growth in Revenue. The Revenue has been growing by 15.37% on average per year.
EPS 1Y (TTM)8.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)1.92%
Revenue growth 3Y-7.36%
Revenue growth 5Y15.37%
Sales Q2Q%28.4%
3.2 Future
Based on estimates for the next years, ICCM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.59% on average per year.
ICCM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 90.27% yearly.
EPS Next Y26.33%
EPS Next 2Y17.81%
EPS Next 3Y18.81%
EPS Next 5Y23.59%
Revenue Next Year-4.67%
Revenue Next 2Y22.65%
Revenue Next 3Y104.63%
Revenue Next 5Y90.27%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ICCM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICCM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ICCM's earnings are expected to grow with 18.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.81%
EPS Next 3Y18.81%
5. Dividend
5.1 Amount
ICCM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ICCM (11/20/2025, 10:10:30 AM)
0.6916
-0.01 (-1.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0.36%
Inst Owner Change26.19%
Ins Owners40.6%
Ins Owner ChangeN/A
Market Cap47.48M
Revenue(TTM)3.29M
Net Income(TTM)-15.58M
Analysts82.22
Price Target2.98 (330.88%)
Short Float %3.05%
Short Ratio0.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.99%
Min EPS beat(2)9.5%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)6.71%
Min EPS beat(4)-4.58%
Max EPS beat(4)26.47%
EPS beat(8)6
Avg EPS beat(8)7.37%
EPS beat(12)9
Avg EPS beat(12)7.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.77%
Min Revenue beat(2)-22.31%
Max Revenue beat(2)-5.23%
Revenue beat(4)0
Avg Revenue beat(4)-13.9%
Min Revenue beat(4)-22.31%
Max Revenue beat(4)-5.23%
Revenue beat(8)2
Avg Revenue beat(8)-16.14%
Revenue beat(12)2
Avg Revenue beat(12)-16.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.61%
PT rev (3m)-3.1%
EPS NQ rev (1m)3.04%
EPS NQ rev (3m)11.12%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-31.51%
Revenue NY rev (1m)-0.99%
Revenue NY rev (3m)-41.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 17.04 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 16.42 | ||
| P/tB | 16.42 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.04
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -147.13% | ||
| ROE | -538.91% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.92% | ||
| FCFM | N/A |
ROA(3y)-89.11%
ROA(5y)-66.89%
ROE(3y)-136.41%
ROE(5y)-102.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.03%
GM growth 5Y4.86%
F-Score3
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 20.57% | ||
| Cap/Sales | 2.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | -15.63 |
F-Score3
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)175.33%
Cap/Depr(5y)260.07%
Cap/Sales(3y)15.28%
Cap/Sales(5y)12.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y26.33%
EPS Next 2Y17.81%
EPS Next 3Y18.81%
EPS Next 5Y23.59%
Revenue 1Y (TTM)1.92%
Revenue growth 3Y-7.36%
Revenue growth 5Y15.37%
Sales Q2Q%28.4%
Revenue Next Year-4.67%
Revenue Next 2Y22.65%
Revenue Next 3Y104.63%
Revenue Next 5Y90.27%
EBIT growth 1Y-10.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.41%
OCF growth 3YN/A
OCF growth 5YN/A
ICECURE MEDICAL LTD / ICCM FAQ
What is the fundamental rating for ICCM stock?
ChartMill assigns a fundamental rating of 2 / 10 to ICCM.
Can you provide the valuation status for ICECURE MEDICAL LTD?
ChartMill assigns a valuation rating of 0 / 10 to ICECURE MEDICAL LTD (ICCM). This can be considered as Overvalued.
Can you provide the profitability details for ICECURE MEDICAL LTD?
ICECURE MEDICAL LTD (ICCM) has a profitability rating of 1 / 10.
How financially healthy is ICECURE MEDICAL LTD?
The financial health rating of ICECURE MEDICAL LTD (ICCM) is 1 / 10.
What is the expected EPS growth for ICECURE MEDICAL LTD (ICCM) stock?
The Earnings per Share (EPS) of ICECURE MEDICAL LTD (ICCM) is expected to grow by 26.33% in the next year.